Obesity drugs regulate neural systems to curb appetite, research reveals

A recent Northwestern Medicine study has identified novel neural circuits modulated by the diabetes and obesity-management ...
Tyla

New study reveals unexpected health benefit from weight loss drugs that could help millions

But now, a scientific study has revealed the surprising way that weight loss and type 2 diabetes drugs could be helping you ...
Odessa American

Global LAG-3 Antagonist Pipeline Insight Report 2021: Emerging Drugs Include Tebotelimab (MacroGenics) & LAG525 (Novartis) – ResearchAndMarkets.com

The "LAG-3 Antagonist – Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com’s offering. This "LAG-3 Antagonist – Pipeline Insight, 2021," report provides comprehensive ...
Medscape

Anti-Obesity Medications Set to Explode Entering 2026

MariTide is now progressing into phase 3 trials, with a focus on its long-term safety and efficacy. Amgen expects to apply ...

How molecular signaling bias can lead to better drug design

About one-third of all drugs approved by the Food and Drug Administration target the largest family of cell membrane ...
Seeking Alpha

Contineum: LPA1R Antagonist Drug Advancement Against IPF With Proven Track Model

Contineum Therapeutics, Inc. (NASDAQ:CTNM) has been able to do well to advance the use of an LPA1R antagonist for the treatment of neuroinflammatory disorders in a phase 1 healthy volunteer study. Why ...
Monthly Prescribing Reference

β-Catenin Antagonist Designated Orphan Drug for Familial Adenomatous Polyposis

ST316 interfered with β-catenin immune-exclusion allowing for stronger cytotoxic T-cell activity. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ST316 for the treatment ...